Proligo LLC, headquartered in Boulder, Colorado, a wholly owned subsidiary of Degussa. Proligo is building the premier nucleic acid chemical supply enterprise. The company is the leading supplier of key ingredients for oligonucleotide manufacturers, supplies innovative specialties for DNA/RNA synthesis applications to the Biopharma/Diagnostic market, supplies active ingredients with highest chemical/biological quality for Genetic Medicines applications, and supplies innovative nucleic acid chemistry technology to the Genomics industry.
CombiMatrix Corporation, formerly Acacia Research-CombiMatrix, is a biotechnology company, with a subsidiary, CombiMatrix Molecular Diagnostics, Inc. (CMDX). CombiMatrix's electrochemical manufacturing process utilizes standard semiconductor technology, software and chemistry to build arrays of materials. The Company's CustomArray products are deoxyribonucleic acid (DNA) microarrays, which have uses in pharmaceutical, biotech and agrochemical industries, as well as in research and government markets. The Company also uses its technology in synergistic internal programs for diagnostics development, drug development, and biodefense in addition to partnerships for nanomaterials development.
Biotage AB, formerly Pyrosequencing AB, is a Sweden-based company active within the biotechnology sector. The Company provides solutions in the areas of medicinal and analytical chemistry, process development and genetic analysis. Its business activities are divided into two segments: Discovery Chemistry and Biosystems. The Discovery Chemistry area supplies systems and consumables within pharmaceutical chemistry, including such areas as synthesis, work-up, purification and evaporation. Its solutions are marketed under the brand names of Initiator, Advancer, ISOLUTE, EVOLUTE, Isolera, FlashMaster and others. The Biosystems area offers systems for genetic analysis, mainly for the use in clinical research. It focuses its operations on two application areas: infectious disease and cancer research. The Biosystems’ activities are based on the Pyrosequencing technology, in which a sample’s deoxyribonucleic acid (DNA) sequences are read in real time with the help of sequencing by synthesis.
TopoTarget A/S is a Denmark-based biotech company. It is focused on treatments for cancer patients and other cancer-related disorders. Its activities cover various aspects of drug development, including assay development, screening, biology, medicinal chemistry, preclinical and clinical trials, regulatory affairs, business development and marketing and sales. TopoTarget’s main product is Savene/Totect. Its clinical pipeline has six drug candidates in Phase II: a clinical compound belinostat (PXD101), oncology products APO866, Siramesine, Baceca, Savicol and the non-oncology drug candidate Avugane. Additionally, it has three oncology products in Phase I development (Zemab, APO010 and Topotect). The Company also has a number of earlier stage cancer products in pre-clinical development, including HDAC inhibitors, as well as HSP90 and mTOR modulators. TopoTarget has operations in Denmark, the United States, Switzerland, the United Kingdom and Germany.
http://www.genzymegenetics.com
Genzyme Genetics is a leading, nationwide provider of high quality genetic testing and genetic counseling services for physicians and their patients. With laboratories and counseling facilities located across the U.S., Genzyme Genetics offers extensive reproductive and cancer testing services, supported by innovative technology and a commitment to quality service and trusted information. Genzyme Genetics is a business unit of Genzyme Corporation.
Interleukin Genetics, Inc. (Interleukin) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the personalized health market. The Company has two primary segments to its business. The first is a personalized health segment primarily focused on researching and developing genetic tests that target the role that genetically determined variations in the inflammatory response have on health and disease. The second segment, comprising the Interleukin brands consumer products business, focuses on developing, selling and marketing nutritional supplements and products into retail consumer channels. (Source: 10-K)
Founded in 1925, ATCC is the world's premier biological resource center. Its mission is to acquire, authenticate, preserve, produce, develop and share biological materials for the advancement of scientific knowledge. ATCC provides these core services in government, industry, education, health care and research laboratories around the world.
Helicos BioSciences Corporation (Helicos) is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. Helicos has developed a technology, called the True Single Molecule Sequencing technology, to facilitate the rapid analysis of large quantities of genetic material by directly sequencing single molecules of deoxyribonucleic acid (DNA) or single DNA copies of ribonucleic acid. Based on this approach, the Company's Helicos Genetic Analysis Platform obtains sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA molecules and imaging the results after each cycle. It consists of an instrument called the HeliScope Single Molecule Sequencer, the HeliScope Analysis Engine, associated reagents and disposable supplies. The system could potentially provide scientists and clinicians with the capability to compare genes and genomes from thousands of individuals. (Source: 10-K)
NimbleGen serves clients worldwide in life sciences, pharmaceuticals, biotechnology, academic research, industrial research, and bio-defense for government agencies. The firm employs about 65 people in its Madison headquarters and has operations in both Iceland and Germany. Baird Venture Partners and Venture Investors of Chicago; Cargill Ventures of Minneapolis, Skyline Ventures of Palo Alto, California; Tactics II Investments LLC of Northbrook, Illinois; the State of Wisconsin Investment Board and the Wisconsin Alumni Research Foundation participated in this latest financial round.
U.S. Genomics has pioneered commercial applications of single molecule DNA, RNA and protein analysis. The company's innovative technologies address high value unmet needs in bio-security, human diagnostics, and food and drug contaminant monitoring. Addressable segments of these markets where the company's technology offers compelling advantage approach $4.0 billion. U.S. Genomics' core genomic mapping technologies are capable of identifying and quantitating individual molecules of DNA, RNA and proteins from a complex sample. Large fragments of genomic DNA are extracted from complex samples utilizing a proprietary sample preparation technology. Universal reagent sets are used, and no target amplification or culture is required. DNA detection using these technologies provides genomic species and strain identification, while quantitation of RNAs and proteins can be used to track expression, all within a highly mutiplexable assay format. The core U.S. Genomics genomic mapping technologies are protected by 60 families of patents with priority dating to the company's foundation in 1997. The universal reagent sets used by the company avoid use of long sequence-specific probes and primers typically associated with PCR thereby enabling broad freedom to operate. U.S. Genomics is pursuing its major market opportunities in partnership with market leaders in each application area. The company's key co-development partners include Northrop Gruman in the field of bio-security. Founded in 1997 and based in Woburn, Massachusetts, U.S. Genomics has raised a total of $61 million from HealthCare Ventures, StillRiver Fund, CB Health Ventures, Fidelity Biosciences Group, Zero Stage Capital and private investors. In addition, the company has been awarded Phase I, II and III contracts totaling $39 million by the U.S. Department of Homeland Security Advanced Research Project Agency (HSARPA) and other U.S. Government agencies to develop a sophisticated biological sensor for biodefense applications.
deCODE genetics, Inc. (deCODE) is a biopharmaceutical company applying its discoveries in human genetics to develop drugs and diagnostics for common diseases. The Company’s population approach and resources enable the Company to isolate genes and drug targets directly involved in the development of the diseases posing challenges to public health. deCODE is turning these discoveries into a growing pipeline of diagnostic tests and therapeutics taking aim at the causes of disease, not just the signs and symptoms. deCODE also offers its consumer genetic analysis service deCODEme. deCODEme enables individual subscribers to have their genome analyzed with approximately one million single-letter markers (SNPs), and to view, on their own secure personal Web interface, whether they carry genetic variants linked by the Company and others to risk of a growing list of common diseases, and to see what their genome can tell them about their ancestry and a number of other non-medical traits. (Source: 10-K)
DNAPrint genomics, Inc. is a development-stage pharmaceutical company. As of March 15, 2007, the Company’s pharmacogenomics products were still in development. The Company generates revenues in its consumer, forensic and genotyping services, but these services have not resulted in the generation of significant revenues. During the year ended December 31, 2006, the Company’s revenues were from the sales of its ancestry product, AncestryByDNA and genotyping services. The Company provides services that range from sequencing and genotyping to the entire process of single nucleotide polymorphisms (SNP) discovery to large industrial customers. Contract genotyping is the process of reading a genetic sequence and identifying differences in the sequence letters. This information helps researchers understand how human differences are expressed at the gene level. (Source: 10KSB)
DNA Sciences, Inc. is focused on the discovery and commercialization of gene-based clinical tests that can determine disease susceptibility, predict disease progress and more effectively manage disease treatment. DNA Sciences collaborates with physicians, researchers and individuals to define the role of genetics in common diseases, particularly cancer, cardiac arrhythmias and diabetes. Individuals, through participation in The DNA Sciences Gene Trust Project(sm) (http://www.DNA.com), help drive both the pace and direction of this research. In addition, individuals and physicians can use http://www.DNA.com to learn about the genetics of many common diseases. DNA Sciences, Inc. is based in Fremont, Calif., and was founded in May 1998.
Benitec Limited is a ribonucleic acid interference (RNAi)-based therapeutics company using its deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi) technology to develop therapies for the treatment of life threatening diseases. The Company’s primary therapeutic program focuses on human immunodeficiency virus (HIV). Its other projects are in the area of infectious diseases and cancer. It also licenses its technology outside of its in-house programs in order to generate revenue to support its corporate and operational activities. During the fiscal year ended June 30, 2008 (fiscal 2008), the principal activity of the Company was the management, funding and commercialization of these projects. It operates in a single segment, including global commercialization (by licensing and partnering) of patents and licenses developed in the area of biotechnology, specifically in functional genomics, with applications in biomedical research and human therapeutics. (Source: ARS)
Genetix was founded by Mark Reid, its current Chief Executive, in 1991 to design and manufacture equipment and consumables for use in genomic research. Genetix has evolved by developing and launching innovative products to address the increasing demand for faster genetic research capabilities. For example, it was instrumental in the development of the 384 well plate, which has now become an industry standard and launched one of the first commercial automated colony pickers.
Promega Corporation is a global leader in providing innovative solutions for the life sciences industry. The company's 1,200 products enable scientists worldwide to advance knowledge in cellular analysis, proteomics, and genomics research with applications in drug discovery, molecular diagnostics, and human identification. Founded in 1978, the company is headquartered in Madison, Wisconsin, USA, and has extensive international distribution.
ProMetic Life Sciences Inc. is a global biopharmaceutical company offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens. The Company is developing products to treat anemia, neutropenia, cancer and autoimmune disease/inflammation. ProMetic uses its Affinity Technology, which employs its Mimetic Ligand technology to facilitate a variety of applications where a target biomolecule requires purification or removal. The Company operates in three units, each of which is a subsidiary controlled by the Company: ProMetic BioSciences Ltd, ProMetic BioTherapeutics, Inc. and ProMetic BioSciences Inc. The Company focuses its activities in two distinct fields: therapeutics and protein technologies. ProMetic develops therapeutics to treat blood-related disorders. ProMetic’s protein technologies are used to remove pathogens from blood and extract and recover valuable proteins from plasma. (Source: ARS)
PowderJect is the world's leading independent vaccine company. The company's headquarters are located in Oxford, UK, and it has facilities located in Europe and the US. With a range of products sold under its Evans Vaccines and SBL Vaccines brands, PowderJect is one of the world's largest vaccines companies. PowderJect's portfolio of products includes vaccines for influenza, yellow fever, travel diarrhoea (ETEC), cholera, tuberculosis, polio and tetanus. The company's biologicals manufacturing facilities are amongst the largest in Europe, and have approvals from both the US and European regulatory authorities. PowderJect's technology focus is on the needle-free powder injection of vaccines, a field in which it leads the world. The company is developing a broad range of vaccines based upon this proprietary delivery technology. PowderJect is also the world leader in the field of DNA vaccines, a revolutionary new method of vaccination that offers the potential to protect against and treat diseases such as hepatitis B and HIV.
Commonwealth Biotechnologies, Inc. (CBI) is a specialized life sciences outsourcing business that offers expertise and a complete range of discovery chemistry and biology products and services, through its subsidiary companies. The subsidiaries of the Company are CBI Services, Fairfax Identity Labs (FIL), Mimotopes Pty Limited (Mimotopes) and Exelgen Limited (Exelgen) (formerly Tripos Discover Research Ltd). (Source: 10KSB)
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory